Three-year survival improves in SMM patients treated with Revlimid, study shows

2 August 2013

US biotech firm Celgene (Nasdaq: CELG) has released positive new data evaluating treatment with Revlimid (lenalidomide) in combination with dexamethasone followed by Revlimid maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma.

The Phase III, randomized, multicenter, open-label study, evaluated whether treatment with the combination of lenalidomide and dexamethasone followed by lenalidomide maintenance in high-risk asymptomatic smoldering multiple myeloma patients prolonged time to progression to symptomatic disease. They were compared with patients who did not receive active treatment and were just observed, which is the current standard of care for smoldering multiple myeloma.

Time to progression increases

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK